Xact Kapitalforvaltning’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Xact Kapitalforvaltning’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$520K	Hold	3,600	–	–	0.01%	742
2019 Q4	$736K	Buy	3,600 +900	+33%	+$164K	0.01%	766
2019 Q3	$217K	Hold	2,700	–	–	﹤0.01%	1353
2019 Q2	$255K	Buy	+2,700	New	+$233K	0.01%	1301

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Xact Kapitalforvaltning's RETA Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) position steady in Q1 2020 at 3,600 shares worth $520K. The position accounts for 0.01% of the portfolio, ranked #742.

Xact Kapitalforvaltning first reported a position in RETA in Q2 2019 and has held it in 4 quarters since. The position peaked at $736K in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q1 2020.

Xact Kapitalforvaltning held 3,600 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $520K as of Q1 2020.
Xact Kapitalforvaltning left its Reata Pharmaceuticals, Inc. Class A Common Stock share count unchanged in Q1 2020.
Reata Pharmaceuticals, Inc. Class A Common Stock made up 0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #742 holding.
Xact Kapitalforvaltning first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and has held it in 4 quarters since.
Xact Kapitalforvaltning's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $736K in Q4 2019.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.